SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-042918
Filing Date
2024-05-14
Accepted
2024-05-14 16:03:36
Documents
68
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205204-10q_tffpharma.htm   iXBRL 10-Q 673912
2 CERTIFICATION ea020520401ex31-1_tffpharma.htm EX-31.1 11865
3 CERTIFICATION ea020520401ex31-2_tffpharma.htm EX-31.2 11539
4 CERTIFICATION ea020520401ex32-1_tffpharma.htm EX-32.1 5176
5 GRAPHIC image_001.jpg GRAPHIC 2935
  Complete submission text file 0001213900-24-042918.txt   3921565

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20240331.xsd EX-101.SCH 50224
7 XBRL CALCULATION FILE tffp-20240331_cal.xml EX-101.CAL 25282
8 XBRL DEFINITION FILE tffp-20240331_def.xml EX-101.DEF 204125
9 XBRL LABEL FILE tffp-20240331_lab.xml EX-101.LAB 361787
10 XBRL PRESENTATION FILE tffp-20240331_pre.xml EX-101.PRE 197721
72 EXTRACTED XBRL INSTANCE DOCUMENT ea0205204-10q_tffpharma_htm.xml XML 314916
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 24944145
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)